Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more
Mangoceuticals, Inc. Common Stock (MGRX) - Total Liabilities
Latest total liabilities as of September 2025: $804.27K USD
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has total liabilities worth $804.27K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mangoceuticals, Inc. Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Mangoceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mangoceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ROCHE HLDG - Dusseldorf Stock Exchang
DU:RHO
|
Germany | €57.20 Billion |
|
Citra Nusantara Gemilang Tbk.
JK:CGAS
|
Indonesia | Rp123.07 Billion |
|
Keynote Financial Services Limited
NSE:KEYFINSERV
|
India | ₹114.13 Million |
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
USA | $1.59 Million |
|
Yong Concrete PCL
BK:YONG
|
Thailand | ฿440.70 Million |
|
Shrinkflex (Thailand) Public Company Limited
BK:SFT
|
Thailand | ฿326.15 Million |
|
Fenbo Holdings Limited Ordinary Shares
NASDAQ:FEBO
|
USA | $50.90 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Mangoceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mangoceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mangoceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual total liabilities of Mangoceuticals, Inc. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.43 Million | +416.40% |
| 2023-12-31 | $276.04K | -29.09% |
| 2022-12-31 | $389.26K | +891.23% |
| 2021-12-31 | $39.27K | -- |